Skip to main content
. 2015 Oct 27;55:595–604. doi: 10.1007/s40262-015-0333-8

Table 3.

Statistical analysis of azilsartan plasma pharmacokinetic parameters according to age, sex, and race

Parameter LS mean LS mean Ratio [90 % CI]
Age Elderly (n = 23) Young (n = 24) Elderly/young
 Single dose (Day 1)
  AUC0–∞ (ng·h/mL) 26,003a 19,062b 1.36 [1.05, 1.77]
  C max (ng/mL) 2876 2093 1.37 [1.02, 1.86]
 Multiple dose (Day 8)
  AUC0–24 (ng·h/mL) 24,375 19,384 1.26 [1.01, 1.57]
  C max (ng/mL) 3036 2638 1.15 [0.89, 1.49]
Sex Female (n = 23) Male (n = 24) Female/male
 Single dose (Day 1)
  AUC0–∞ (ng·h/mL) 22,577a 21,955b 1.03 [0.78, 1.36]
  C max (ng/mL) 2478 2430 1.02 [0.75, 1.39]
 Multiple dose (Day 8)
  AUC0–24 (ng·h/mL) 22,565 20,938 1.08 [0.86, 1.36]
  C max (ng/mL) 3049 2627 1.16 [0.89, 1.52]
Race White (n = 24) Black (n = 23) White/black
 Single dose (Day 1)
  AUC0–∞ (ng·h/mL) 24,599b 20,150a 1.22 [0.95, 1.58]
  C max (ng/mL) 2547 2364 1.08 [0.81, 1.44]
 Multiple dose (Day 8)
  AUC0–24 (ng·h/mL) 22,974 20,565 1.12 [0.90, 1.39]
  C max (ng/mL) 3201 2502 1.28 [0.99, 1.65]

CI confidence interval, AUC 0–24h area under the plasma concentration-time curve from time 0 to 24 h post dose, AUC 0–∞ area under the plasma concentration-time curve from time 0 h to infinity, C max maximum observed drug concentration in plasma

a n = 22

b n = 23